Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

2.68
+0.11004.28%
Post-market: 2.750.0699+2.61%19:58 EDT
Volume:16.67M
Turnover:43.33M
Market Cap:894.94M
PE:-2.17
High:2.71
Open:2.50
Low:2.45
Close:2.57
Loading ...

Iovance Biotherapeutics Inc. Conducted Annual Stockholder Meeting Virtually

Reuters
·
11 Jun

Unusually active option classes on open June 9th

TIPRANKS
·
09 Jun

Chief Commercial Officer Daniel Gordon Kirby Acquires Common Shares of Iovance Biotherapeutics Inc

Reuters
·
07 Jun

Goldman Sachs Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
03 Jun

Iovance Biotherapeutics (IOVA) Receives a Hold from Citizens JMP

TIPRANKS
·
03 Jun

Iovance Biotherapeutics announces publication of five-year analysis of Amtagvi

TIPRANKS
·
02 Jun

Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays

TIPRANKS
·
02 Jun

Wells Fargo Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)

TIPRANKS
·
23 May

Iovance Biotherapeutics announces five-year results of Amtagvi in melanoma

TIPRANKS
·
23 May

BRIEF-Iovance Announces Five-Year Results Of Amtagvi® (Lifileucel) In Patients With Advanced Melanoma At Asco Annual Meeting

Reuters
·
23 May

BRIEF-Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
17 May

Frederick G. Vogt, Interim CEO & General Counsel, Reports Acquisition of Common Shares in Iovance Biotherapeutics Inc

Reuters
·
17 May

BUZZ-UBS downgrades Iovance on sluggish uptake of skin cancer drug

Reuters
·
17 May

UBS Downgrades Iovance Biotherapeutics to Neutral From Buy, Adjusts Price Target to $2 From $17

MT Newswires Live
·
16 May

Iovance Biotherapeutics Cut to Neutral From Buy by UBS

Dow Jones
·
16 May

Iovance Biotherapeutics downgraded to Neutral from Buy at UBS

TIPRANKS
·
16 May

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
12 May

Truist Downgrades Iovance Biotherapeutics to Hold From Buy, After Q1 Sales Miss, Guidance Cut

MT Newswires Live
·
12 May

Stock Track | Iovance Biotherapeutics (IOVA) Soars 5.14% Pre-market on Bullish Analyst Sentiment

Stock Track
·
12 May

Iovance Biotherapeutics price target lowered to $4 from $5 at Barclays

TIPRANKS
·
12 May